Therefore, once the threshold values of sclerostin and PGE2 are standardized through larger studies such as cohort, these biomarkers in GCF samples obtained at diagnosis and post-treatment could be valuable within a clinical workflow for identifying AP status and monitoring its management. This evidence concerns the gene SOST and alkaline phosphatase measurement.